Earnings results for Satsuma Pharmaceuticals (NASDAQ:STSA)
Satsuma Pharmaceuticals, Inc. is estimated to report earnings on 03/16/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.56. The reported EPS for the same quarter last year was $-0.62.
Analyst Opinion on Satsuma Pharmaceuticals (NASDAQ:STSA)
4 Wall Street analysts have issued ratings and price targets for Satsuma Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.25, predicting that the stock has a possible downside of 20.93%. The high price target for STSA is $7.00 and the low price target for STSA is $3.50. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of “Hold.”
Satsuma Pharmaceuticals has received a consensus rating of Hold. The company’s average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings. According to analysts’ consensus price target of $5.25, Satsuma Pharmaceuticals has a forecasted downside of 20.9% from its current price of $6.64. Satsuma Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Satsuma Pharmaceuticals (NASDAQ:STSA)
Satsuma Pharmaceuticals does not currently pay a dividend. Satsuma Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Satsuma Pharmaceuticals (NASDAQ:STSA)
In the past three months, Satsuma Pharmaceuticals insiders have not sold or bought any company stock. 45.65% of the stock of Satsuma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. 56.37% of the stock of Satsuma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Satsuma Pharmaceuticals (NASDAQ:STSA
Earnings for Satsuma Pharmaceuticals are expected to grow in the coming year, from ($2.49) to ($1.06) per share. The P/E ratio of Satsuma Pharmaceuticals is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Satsuma Pharmaceuticals is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Satsuma Pharmaceuticals has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here